Erik J. Uhlmann

Erik J. Uhlmann

Auto-generated profile, based on publicly available information

Erik J. Uhlmann

Beth Israel Deaconess Medical Center , Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in iScience
Verified
Journal Article
Open access
AZAiliang Zeng
Ailiang Zeng
ZWZhiyun Wei
Zhiyun Wei
RRRosalia Rabinovsky
Rosalia Rabinovsky
HJHyun Jung Jun
Hyun Jung Jun
RFRachid El Fatimy
Rachid El Fatimy
AKAnna M. Krichevsky
Anna M. Krichevsky
Glioblastoma (GBM) may arise from astrocytes through a multistep process involving a progressive accumulation of mutations. We explored whether GBM-derived extracellular vesicles (EVs) may facilitate neoplastic transformation and malignant growth of astrocytes. We utilized conditioned media (CM) of cultured glioma cells, its sequential filtration, diverse cell-based assays, RNA sequencing, and metabolic assays to compare the effects of EV-containing and EV-depleted CM. GBM EVs facilitated the neoplastic growth of pre-transformed astrocytes but not normal human or mouse astrocytes. They induced proliferation, self-renewal, and colony formation of pre-transformed astrocytes and enhanced astrocytoma growth in a mouse allograft model. GBM EVs appear to reprogram astrocyte metabolism by inducing a shift in gene expression that may be partly associated with EV-mediated transfer of full-length mRNAs encoding ribosomal proteins, oxidative phosphorylation, and glycolytic factors. Our study suggests an EV/extracellular RNA (exRNA)-mediated mechanism that contributes to astrocyte transformation via metabolic reprograming and implicates horizontal mRNA transfer.

6 April 2022 in Molecular Cell
Verified
Journal Article
Closed access
EDEvgeny Deforzh
Evgeny Deforzh
EUErik J. Uhlmann
Erik J. Uhlmann
EDEashita Das
Eashita Das
AGAleksandra Galitsyna
Aleksandra Galitsyna
RARamil Arora
Ramil Arora
AKAnna M. Krichevsky
Anna M. Krichevsky

4 March 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
EMEric J. Miller
Eric J. Miller
RPRushad Patell
Rushad Patell
EUErik J. Uhlmann
Erik J. Uhlmann
SRSiyang Ren
Siyang Ren
HSHannah Southard
Hannah Southard
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
Although intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there are limited data on the influence of antiplatelet agents on the development of brain tumor–associated ICH. To evaluate whether the administration of antiplatelet agents increases the risk of ICH, we performed a matched cohort analysis of patients with metastatic brain tumors with blinded radiology review. The study population included 392 patients with metastatic brain tumors (134 received antiplatelet agents and 258 acted as controls). Non–small cell lung cancer was the most common malignancy in the cohort (74.0%), followed by small cell lung cancer (9.9%), melanoma (4.6%), and renal cell cancer (4.3%). Among those who received an antiplatelet agent, 86.6% received aspirin alone and 23.1% received therapeutic anticoagulation during the study period. The cumulative incidence of any ICH at 1 year was 19.3% (95% CI, 14.1-24.4) in patients not receiving antiplatelet agents compared with 22.5% (95% CI, 15.2-29.8; P = .22, Gray test) in those receiving antiplatelet agents. The cumulative incidence of major ICH was 5.4% (95% CI, 2.6-8.3) among controls compared with 5.5% (95% CI, 1.5-9.5; P = .80) in those exposed to antiplatelet agents. The combination of anticoagulation plus antiplatelet agents did not increase the risk of major ICH. The use of antiplatelet agents was not associated with an increase in the incidence, size, or severity of ICH in the setting of brain metastases.

11 July 2025 in Neuro-Oncology
Verified
Journal Article
Open access
YZYanhong Zhang
Yanhong Zhang
RRRosalia Rabinovsky
Rosalia Rabinovsky
EDEvgeny Deforzh
Evgeny Deforzh
AKAmi Kobayashi
Ami Kobayashi
AKAnastasia Kuzkina
Anastasia Kuzkina
AKAnna M. Krichevsky
Anna M. Krichevsky
Background: Glioblastoma (GBM), one of the deadliest cancers, resists current therapies, with drug development hindered by its high heterogeneity. However, GBM consistently relies on microRNA-10b (miR-10b), a key driver of glioma growth and a promising therapeutic target. miR-10b gene editing represents a potential treatment, but effective delivery strategies for gene editing systems in GBM remain unexplored. Methods: We developed lipid nanoparticles (LNPs) encapsulating Cas9 mRNA and a miR-10b-targeting sgRNA (termed miRTEN). miRTEN was tested in glioma stem cells (GSCs) and orthotopic GBM models to assess therapeutic efficacy, immune responses, and safety. Results: Intracerebroventricular injections of miRTEN enabled broad and durable Cas9 mRNA expression and miR-10b gene editing in tumor core and invasive areas across diverse GBM models. miRTEN significantly suppressed tumor growth, reduced GSC proliferation and viability, with therapeutic outcomes correlating with dose-dependent miR-10b suppression. Combining miRTEN with temozolomide (TMZ) further enhanced tumor suppression, overcoming TMZ resistance and improving survival. In immunocompetent models, miRTEN activated antitumor immune responses, increased cytotoxic CD8+ T cells infiltration, and promoted durable immune memory, enabling tumor rejection upon rechallenge. Safety assessments demonstrated that miRTEN selectively targets GBM cells, sparing normal brain tissues and causing no significant off-target toxicity. Conclusion: As in vivo CRISPR-based drugs advance toward clinical applications, our findings demonstrate the potential of LNPs-mediated CRISPR–Cas9 systems for targeted miR-10b editing and, more generally, gene editing and RNA therapies for GBM. miRTEN monotherapy, as well as its combination with standard care, offers a promising, safe, and effective approach to improving outcomes in GBM.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
DRDavid A. Reardon
David A. Reardon
AAAjay P Abad
Ajay P Abad
WCWilliam T. Curry
William T. Curry
EWEric T Wong
Eric T Wong
RFRobert Fenstermaker
Robert Fenstermaker
2016 Background: SVN53-67/M57-KLH (SurVaxM) is a novel cancer vaccine designed to stimulate an immune response targeting the tumor-specific antigen survivin. A multi-center, single-arm phase 2 clinical trial of SurVaxM in survivin-positive newly diagnosed glioblastoma (nGBM, NCT02455557) is now fully enrolled and data updated. Methods: Patients (n = 63) with nGBM were enrolled at 5 US cancer centers and followed for safety, 6-month progression-free survival (PFS6), 12-month overall survival (OS12) and immunologic response. All patients underwent craniotomy with near-total resection ( < 1 cm3 residual contrast enhancement), TMZ chemoradiation, adjuvant TMZ and SurVaxM. Patients received 4 doses of SurVaxM (500 mcg) in Montanide with sargramostim (100 mcg) biweekly, followed by maintenance SurVaxM with adjuvants every 12 weeks until tumor progression. Immunogenicity of SurVaxM was assessed by detection of survivin-specific antibody (IgG) and CD8+ T-cell levels. Results: Median age was 60 yrs (range, 20-82), 53% methylated MGMT, 46% unmethylated MGMT (1 N/A) and 60% were male. Survivin expression ranged from 1-40% (median 12%) by immunohistochemistry. Median time to first immunization was 3.0 mo (1.9-4.0 mo) from diagnosis. There have been no RLT or grade ≥ 3 SAE attributable to SurVaxM. The most common AE was grade 1-2 injection site reactions. OS12 was 86% from first immunization and 93.4% from diagnosis. OS12 for meMGMT was 93.1% and unMGMT was 78% from first immunization. Median time to tumor progression (mPFS) was 13.9 months from diagnosis. Median OS has not yet been reached. SurVaxM produced an increase in survivin-specific IgG titre from pre-vaccine baseline to ≥ 1:10,000 in 67% of pts and ≥ 1:100,000 in 27%. CD8+ T cell responses were observed. Anti-survivin IgG and OS were correlated. Conclusions: SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in nGBM and has minimal toxicity. A randomized, prospective trial of SurVaxM in nGBM is planned. Clinical trial information: NCT024455557.

1 September 2024 in Radiology
Verified
Journal Article
Closed access
MBMehran Baboli
Mehran Baboli
FWFuyixue Wang
Fuyixue Wang
ZDZijing Dong
Zijing Dong
JDJorg Dietrich
Jorg Dietrich
EUErik J. Uhlmann
Erik J. Uhlmann
OAOvidiu Andronesi
Ovidiu Andronesi
Fast super-resolution whole-brain MR spectroscopic imaging integrated with multiparametric echo-planar time-resolved imaging for relaxation and proton density correction yielded absolute metabolite quantification at 2.4-mm isotropic resolution in human gliomas and healthy brains.